XML 63 R34.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Financial Instruments - Additional Information (Details) - shares | 1 Months Ended | 12 Months Ended
--- | --- | ---
May 31, 2017 | Dec. 31, 2016
IPO | Series A-1 Preferred Shares |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Stock issued during period upon conversion of warrants, shares | 364,036 |
A-1 Warrants |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value assumptions, expected volatility rate |  | 73.93%
A-1 Warrants | Allergan |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value inputs discount rates |  | 10.50%
A-1 Warrants | Internal Development |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value inputs discount rates |  | 19.00%
A-1 Warrants | IPO | Series A-1 Preferred Shares |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Stock issued during period upon conversion of warrants, shares | 364,036 |
A-1 Warrants | Hybrid Method Valuation Technique | IPO |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value inputs, probability of estimated rate |  | 20.00%
A-1 Warrants | Hybrid Method Valuation Technique | Liquidation Event |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value inputs, probability of estimated rate |  | 80.00%
A-1 Warrants | Minimum [Member] |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value inputs discount rates |  | 10.50%
A-1 Warrants | Maximum |  |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] |  |
Fair value inputs discount rates |  | 19.00%

X
- Definition Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsDiscountRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueInputsProbabilityOfDefault
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=urgn_InternalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=urgn_HybridMethodValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=urgn_LiquidationEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |